Actinium Pharmaceuticals, Inc.

Leadership Team

View Bio
Ryan Chu, CFA

Ryan Chu, CFA

Vice President, Finance and Investor Relations

Ryan Chu, CFA

Ryan Chu, CFA

Vice President, Finance and Investor Relations

Ryan Chu brings over two decades of experience across healthcare investing, capital markets, and life sciences operations. Most recently, he served as Director of Research for Healthcare at Guidepoint, where he led primary research and strategic diligence initiatives supporting institutional investors, private equity firms, and corporate clients across biopharmaceuticals, diagnostics, and medical technology. Previously, Ryan held investment roles at Quad Group, Suffolk Capital, and Brant Point, where he focused on healthcare investments spanning biotechnology and medical technology companies. Earlier in his career, he worked in healthcare investment banking at SG Cowen and in equity research at Morgan Stanley. Ryan also co-founded a medical equipment company, serving as Chief Commercial and Financial Officer. He holds a B.S. in Molecular Biophysics & Biochemistry from Yale University and is a CFA Charterholder.

View Bio
Paul Diamond, Ph.D., Esq.

Paul Diamond, Ph.D., Esq.

Vice President, Legal and Intellectual Property Counsel

Paul Diamond, Ph.D., Esq.

Paul Diamond, Ph.D., Esq.

Vice President, Legal and Intellectual Property Counsel

Paul Diamond was appointed Vice President, Patent and Legal Counsel in July 2021.  He brings over twenty years of experience counseling life science companies on complex patent and commercial matters.  Prior to joining Actinium Pharmaceuticals, Paul led the in-house legal team at a publicly traded clinical diagnostics company.  He has practiced with the intellectual property group of global law firm White & Case LLP and at a number of nationally recognized law firms.   Paul received a J.D. from Fordham University School of Law, a Ph.D. (Molecular and Cellular Biology) from Harvard University, and a B.A. (Biology) from the Johns Hopkins University.

View Bio
Julie Gibson

Julie Gibson

Vice President, Portfolio and Clinical Operations

Julie Gibson

Julie Gibson

Vice President, Portfolio and Clinical Operations

With nearly three decades of experience in pharmaceutical drug development, Julie is a proven leader across clinical operations, asset leadership and CMC management. Throughout a career defined by building and guiding high-performing teams, Julie has worked on small molecules, biologics, radiopharmaceuticals, and medical devices, driving programs from early-stage development through commercial launch. She served as Vice President of Global Clinical Operations at Telix Pharmaceuticals, overseeing a global radiopharmaceutical portfolio spanning renal, prostate, brain, and rare disease oncology. In this role, Julie led a diverse international team and set clinical corporate objectives. She also headed up Global Clinical Operations at Baxter Healthcare for six therapeutic areas, redefining organizational infrastructure and processes, and managing a robust team across clinical, finance, and supply chain functions. At Takeda Pharmaceuticals, Julie led the CMC Program Leadership Team, managing a CMC portfolio of over 40 programs, leading international teams, and playing a key role in global asset strategy and diversity initiatives—including serving as site lead in Osaka Japan and founding the Women’s Inclusion Network.

View Bio
Adeela Kamal, PhD

Adeela Kamal, PhD

Executive Vice President, Head of Research and Development

Adeela Kamal, PhD

Adeela Kamal, PhD

Executive Vice President, Head of Research and Development

Adeela is a seasoned R&D executive with 25 years of experience in biotech and pharma, focused on the discovery and development of targeted Oncology therapies. She has led programs from early discovery through regulatory approval, contributing to 20+ Development Candidates, 12+ IND filings, and three approved cancer therapies across solid tumors and hematological malignancies. Her expertise spans the full R&D continuum—including target identification, lead generation/optimization for multiple modalities (small molecules, mAbs, bispecifics, ADCs, radioconjugates, immunotoxins, peptides), computational biology, nonclinical safety, CMC, translational medicine, clinical biomarkers, and regulatory submissions (IND/BLA/NDA). Prior to joining Actinium, Adeela served as SVP, Head of Biology and Translational Medicine at SpringWorks Therapeutics and previously as VP, Head of R&D at Emergent BioSolutions. She held earlier scientific leadership roles at Ferring Pharmaceuticals, AstraZeneca, Biogen, and Conforma Therapeutics. Adeela earned her B.S. in Biology from MIT, her Ph.D. in Molecular and Cell Biology from UT Southwestern and completed postdoctoral training with a fellowship from the Howard Hughes Medical Institute. She has published 40+ peer-reviewed articles, holds multiple patents and is a speaker at leading Oncology conferences.

View Bio
Monideepa Roy, Ph.D.

Monideepa Roy, Ph.D.

Senior Vice President, Corporate Development – R&D

Monideepa Roy, Ph.D.

Monideepa Roy, Ph.D.

Senior Vice President, Corporate Development – R&D

Monideepa leads corporate development initiatives at Actinium, driving business outcomes around R&D efforts. Before joining Actinium, she was Founder and interim CEO of Akamara Therapeutics, Inc., an early-stage oncology drug development company. Prior to Akamara, she was a founding member of Invictus Oncology, developing novel I/O and conjugated antibody therapies. Before moving to industry, Monideepa was a Lecturer at Harvard University, a Leukemia and Lymphoma Society Special Fellow at Brigham and Women’s Hospital and Research Fellow at Harvard Medical School where she was funded by the US Department of Defense and was awarded the first Thomas Gill Prize for Research Excellence. She received her Ph.D. in Molecular Biology from Jawaharlal Nehru University, New Delhi, Master's in Biophysics and Molecular Biology from the University College of Science and Bachelor's degree in Human Physiology (Honors) from Presidency College, Calcutta.

View Bio
Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board

Sandesh has 25+ years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Sandesh was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Sandesh has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Sandesh was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.

View Bio
Gary Siegel

Gary Siegel

Vice President, Controller

Gary Siegel

Gary Siegel

Vice President, Controller

Gary is responsible for the preparation of the Company’s financial reporting, including reports filed with the Securities and Exchange Commission, or SEC. Gary has many years of experience working for public companies. Prior to joining Actinium, he was Controller at Bellerophon Therapeutics, Inc., a public medical device company, and prior to that, he was Vice President Finance of Cogentix Medical, Inc., a public medical device company. From 2003 to 2013, Gary was with Genta Incorporated, a public biopharmaceutical company, where he progressed to be Vice President-Finance and Principal Financial Officer. Earlier in his career, Gary had a number of positions at Pfizer Inc. Gary has an MBA from Carnegie-Mellon University.

View Bio
Madhuri Vusirikala, M.D.

Madhuri Vusirikala, M.D.

Vice President, Clinical Development BMT and Cellular Therapy

Madhuri Vusirikala, M.D.

Madhuri Vusirikala, M.D.

Vice President, Clinical Development BMT and Cellular Therapy

Madhuri is an accomplished bone marrow transplant physician and hematologist with over 20 years of clinical experience. She is board certified in internal medicine, hematology and oncology. Madhuri joins Actinium from UT Southwestern Medical Center in Dallas, Texas, where she has been a Professor of Internal Medicine in the Division of Hematology/Oncology and Medical Director of the Adult Allogeneic Bone Marrow Transplant Program. She specialized in managing a variety of hematologic malignancies and performing allogeneic bone marrow transplants for these patients when indicated. She also served as primary investigator for most of the clinical trials at UT Southwestern related to BMT. Madhuri earned her medical degree (M.B.B.S.) at India’s Lady Hardinge Medical College before completing an internal medicine internship at Maulana Azad Medical College-Delhi University and an internal medicine internship and residency at The State University of New York, Syracuse. She also completed a hematology and oncology fellowship at the University of Pittsburgh and an advanced fellowship in bone marrow transplantation at Vanderbilt University Medical Center. Madhuri is a member of the American Society of Hematology, American Society of Transplantation and Cellular Therapy. She serves as a member on the NCCN panels for Hematopoietic Cell Transplantation and Acute Lymphoblastic Leukemia committees.

Email Sign Up

Receive the latest news, events and updates!

Sign Up Now